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RESEARCH
Loss of the PTCH1 tumor suppressor defines 
a new subset of plexiform fibromyxoma
Sudeep Banerjee1,2, Christopher L. Corless3, Markku M. Miettinen4, Sangkyu Noh1, Rowan Ustoy1, 
Jessica L. Davis3, Chih‑Min Tang1, Mayra Yebra1, Adam M. Burgoyne5 and Jason K. Sicklick1*
Abstract 
Background: Plexiform fibromyxoma (PF) is a rare gastric tumor often confused with gastrointestinal stromal tumor. 
These so‑called “benign” tumors often present with upper GI bleeding and gastric outlet obstruction. It was recently 
demonstrated that approximately one‑third of PF have activation of the GLI1 oncogene, a transcription factor in the 
hedgehog (Hh) pathway, via a MALAT1‑GLI1 fusion protein or GLI1 up‑regulation. Despite this discovery, the biology 
of most PFs remains unknown.
Methods: Next generation sequencing (NGS) was performed on formalin‑fixed paraffin‑embedded (FFPE) samples 
of PF specimens collected from three institutions (UCSD, NCI and OHSU). Fresh frozen tissue from one tumor was 
utilized for in vitro assays, including quantitative RT‑PCR and cell viability assays following drug treatment.
Results: Eight patients with PF were identified and 5 patients’ tumors were analyzed by NGS. An index case had a 
mono‑allelic PTCH1 deletion of exons 15–24 and a second case, identified in a validation cohort, also had a PTCH1 
gene loss associated with a suspected long‑range chromosome 9 deletion. Building on the role of Hh signaling in PF, 
PTCH1, a tumor suppressor protein, functions upstream of GLI1. Loss of PTCH1 induces GLI1 activation and down‑
stream gene transcription. Utilizing fresh tissue from the index PF case, RT‑qPCR analysis demonstrated expression of 
Hh pathway components, SMO and GLI1, as well as GLI1 transcriptional targets, CCND1 and HHIP. In turn, short‑term 
in vitro treatment with a Hh pathway inhibitor, sonidegib, resulted in dose‑dependent cell killing.
Conclusions: For the first time, we report a novel association between PTCH1 inactivation and the development of 
plexiform fibromyxoma. Hh pathway inhibition with SMO antagonists may represent a target to study for treating a 
subset of plexiform fibromyxomas.
Keywords: Submucosal tumor, Gastric mass, Patched 1, GLI1, Hedgehog pathway, SMO inhibitor, Sonidegib, 
Gastrointestinal stromal tumor, Next generation sequencing
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Background
Plexiform fibromyxoma (PF) is a rare submucosal gas-
tric tumor with unknown incidence that can be confused 
with myxoid gastrointestinal stromal tumors (GIST) [1]. 
While slow growth and lack of metastases suggest an 
indolent natural history, these so-called “benign” tumors 
often present with upper gastrointestinal bleeding and 
gastric outlet obstruction. Although the cell of ori-
gin remains unknown, PF generally occurs in the gas-
tric muscularis propria and frequently invades into the 
mucosa and submucosa [1–4]. Histologically, PF is char-
acterized by a multinodular plexiform growth pattern, 
diffuse myxoid stroma and prominent thin arborizing 
capillaries. Immunohistochemically, PF is characterized 
by expression of α-SMA (alpha smooth muscle actin) 
while lacking expression for CD117 (KIT, c-KIT), DOG-1 
(discovered on GIST-1), CD34, S-100, desmin (or focal), 
and cytokeratins. On this basis, PF can be differenti-
ated from GIST, as well as leiomyoma, leiomyosarcoma, 
schwannoma, gastric carcinoids, and desmoids [1, 3].
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To date, there has been only one report investigat-
ing the molecular biology of PF. The authors demon-
strated that 5 of 16 tumors had activation of the GLI1 
oncogene, a transcription factor in the hedgehog (Hh) 
pathway [5]. Two tumors were found to have GLI1 
amplification, while three had MALAT1-GLI1 onco-
genic fusions. Both types of GLI1 genomic alterations 
resulted in overexpression of GLI1 protein and activa-
tion of Hh signaling. This highly conserved pathway 
has been implicated in the biology of several types of 
cancers, including gastroblastoma [6], basal cell car-
cinoma [7], medulloblastoma [8], rhabdomyosarcoma 
[9], hepatocellular carcinoma [10], and GIST [11], as 
well as tumors with plexiform and fibromyxoid histol-
ogies [12]. The pathway is activated when the hedge-
hog ligands, namely sonic hedgehog (SHH), indian 
hedgehog (IHH) and desert hedgehog (DHH) ligands, 
bind to their receptor, Patched 1 (PTCH1), a multi-
pass transmembrane protein. In an unbound state, 
PTCH1 negatively regulates smoothened (SMO), a 
seven-transmembrane domain proto-oncoprotein. Fol-
lowing ligand binding, the PTCH1 tumor suppressor 
protein releases SMO inhibition, which then leads to 
activation of the GLI family of transcription factors 
that includes the GLI1 proto-oncoprotein. In turn, 
GLI1 regulates expression of many genes involved in 
cell cycle progression, including Cyclin D1 (CCND1), 
as well as members of the Hh pathway itself, includ-
ing PTCH1, GLI1, and hedgehog-interacting protein 
(HHIP) [13]. Thus, oncogenic mutation of SMO or 
GLI1, as well as inactivating mutations of PTCH1 can 
activate the pathway and downstream transcription 
[13]. However, only SMO and PTCH1-altered tumors 
can be targeted with the three FDA-approved SMO 
inhibitors, namely sonidegib (Novartis/Sun), vismod-
egib (Genetech-Roche), and glasdegib (Pfizer).
The PTCH1 tumor suppressor gene is located on the 
long arm of chromosome 9 (9q22.32). Over 500 differ-
ent PTCH1 mutations have been implicated in Gorlin 
syndrome (i.e., basal cell carcinoma and rhabdomyo-
sarcoma), sporadic basal cell carcinoma, holoprosen-
cephaly, keratocystic odontogenic tumors, and ocular 
developmental anomalies [14]. Herein, we present the 
first report of recurrent PTCH1 loss in plexiform fibro-
myxoma based on next generation sequencing. This 
newly identified genetic alteration is the first tumor 
suppressor associated with PF tumorigenesis. In turn, 
we examined the role of PTCH1 inactivation on Hh 
signaling and investigated a rational approach to phar-
macologically treating PTCH1-, but not GLI1-mutated 
PF, with SMO inhibitors.
Methods
Human subjects
Written informed consent was obtained for all study 
participants, including publication of clinical data. 
Patient tissue collection, acquisition of clinical data, 
and conducting experimental procedures on biologi-
cal samples was approved or exempt by each institu-
tional IRB [UC San Diego Human Research Protections 
Program Institutional Review Board (IRB) Protocol 
#090401, NCI Office of Human Subjects Research 
(OHSR) IRB exemption was granted for work with 
anonymized annotated human samples, and OHSU IRB 
exemption was granted for contribution of one patient 
to the study cohort]. All experiments were conducted in 
accordance with appropriate regulatory guidelines for 
use of human tissue. Excess explant tissue was collected 
for study. An index case from UCSD served as the ini-
tial observation for this study. Additional patients were 
retrospectively identified from the NCI and OHSU. 
These were analyzed in a validation cohort.
Pathologic diagnosis
Pathologic diagnosis was performed at each institution. 
In general, pathologic diagnosis of PF requires histopa-
thology showing spindle shaped cells, diffuse or focally 
plexiform architecture, prominent thin capillaries and 
a bland myxoid background. Additionally, immuno-
histochemical staining is characteristically positive for 
α-SMA while negative for CD117, CD34, DOG-1, and 
S-100.
Primary tumor dissociation and single cell suspension
Excess fresh tumor tissue was dissociated into sin-
gle cell suspensions using the gentleMACS Disso-
ciator (Miltenyi Biotec, San Diego, CA) as previously 
described [15]. Solid tissues were cut into 5-mm size 
pieces and were transferred to a gentleMACS C-Tube 
containing RPMI 1640 media and MACS human tumor 
dissociation enzyme solution (Miltenyi Biotec) accord-
ing to manufacturer’s instructions for tough tumor 
tissue (h_Tumor_01). The sample was then passed 
through a 70  μm filter, and tumor cells were collected 
following centrifugation. The single cells were cultured 
in RPMI 1640 supplemented with 20% fetal bovine 
serum (FBS), 1% penicillin/streptomycin (Mediatech, 
Manassas, VA) and 2 mM glutamine (Mediatech).
Next generation sequencing
Sequencing was performed on formalin-fixed paraffin-
embedded (FFPE) sections (6 tumors from National 
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Cancer Institute (NCI), 1 tumor from Oregon Health 
& Science University (OHSU) and 1 tumor from Uni-
versity of California, San Diego (UCSD). Foundation-
One-Heme Next Generation Sequencing (NGS) was 
performed on Tumor 1 as previously described [16]. 
Briefly, DNA was extracted from FFPE sections with a 
minimum of 20% tumor tissue. DNA was submitted for 
comprehensive genomic profiling with hybridization-
captured, adaptor ligation-based libraries. The Foun-
dationOne-Heme test interrogates a cancer-related 
library of 400 gene-associated genes, 30 introns and 
250 RNA transcripts tailored for hematologic malig-
nancy and sarcoma [17]. Tumors 2–5 were analyzed 
by the GeneTrails Comprehensive Solid Tumor Panel 
(Knight Diagnostic Laboratories, OHSU), which is a 
DNA sequencing panel that screens for alterations in 
124 known oncogenes and tumor suppressor genes. 
DNA extracted from FFPE tumor tissue must provide 
a minimum of 50  ng DNA content, which is required 
to achieve a minimum depth of 250 reads per ampli-
con. Samples that had less than this minimum required 
DNA content did not undergo NGS analysis. In addi-
tion, Tumors 2–5 were subjected to RNA sequencing 
using the GeneTrails Solid Tumor Fusion Gene Panel 
(Knight Diagnostic Laboratories, OHSU), which is a 
partner-agnostic assay for gene fusions across 22 can-
cer-related target genes. RNA extracted from FFPE 
tumor tissue required a minimum of 30  ng RNA con-
tent for adequate analysis. Samples with less than the 
required amount were not analyzed by RNASeq.
RNA preparation and expression quantification
Total RNA for in  vitro experiments was prepared from 
single cell suspension using the RNeasy Mini Kit (Qia-
gen, Hilden, Germany). RNA quality was assessed with 
the Nanodrop 2000 (Thermo Scientific, Waltham, MA). 
Reverse transcription quantitative real-time polymerase 
chain reaction (RT-qPCR) was performed on a CFX96 
real-time system (Bio-Rad Laboratories, Hercules, CA) 
using SsoFast EvaGreen Supermix (Bio-Rad Laborato-
ries). Each sample was tested in triplicate. Forward and 
reverse primer sequences are as previously described [10, 
18]. The threshold cycle (Ct) of target genes were normal-
ized to ACTB according to delta-Ct method [18]. PCR 
transcript expression and appropriate size were validated 
by gel electrophoresis using a 2.0% agarose gel in 1× 
Tris–acetate-EDTA buffer.
Cell viability assay
Single cell suspensions of tumor cells were seeded at 2500 
cells per well on a 96-well plate (Corning, Lowell, MA). 
The cells were grown for 48 h and subsequently treated 
with Sonidegib (LDE225, Novartis, Basel, Switzerland) 
with a titration of 50-, 25-, 12.5- and 6.25-μM for 72  h 
based upon prior reports in mantle cell lymphoma, rhab-
domyosarcoma, and chronic myeloid leukemia [19–21]. 
The CellTiter-Glo Luminescent Cell Viability Assay (Pro-
mega, Madison, WI) was performed and luminescence 
measured on the Tecan Infinite 200 microplate reader 
(Tecan, Männedorf, Switzerland).
Statistical analysis
Statistical analyses were performed using Prism Graph-
Pad 7 (GraphPad Software, La Jolla, CA). Results are 
expressed as mean ± standard deviation. Comparison 
were made using student’s t-test and statistical signifi-
cance was accepted at the 5% level. Inhibitor concentra-
tion-50  (IC50) was calculated using GraphPad 7.
Results
Patient demography
Overall, eight cases of pathology confirmed plexiform 
fibromyxoma were examined from three institutions. An 
index case (Tumor 1) served as the initial observation 
and then seven additional patients were retrospectively 
identified and analyzed in a validation cohort (Table  1). 
Overall, the median age at diagnosis was 45.5  years old 
(range 16–65 years). There were five females (62.5%) and 
three males in the cohort. Tumor locations were distrib-
uted throughout the stomach, except one tumor that 
was described as originating from the duodenum. The 
median tumor size was 3.5 cm (range 2.8–11 cm).
Next generation sequencing (NGS)
DNA and RNA extraction were performed on FFPE sam-
ples for all tumors. DNA extraction met minimum qual-
ity requirements in 4 out of 8 samples (50%) and RNA 
extraction met minimum quality requirements in 5 out 
of 8 samples (62.5%). NGS was performed by either the 
FoundationOne-Heme Panel (Tumor 1, Foundation 
Medicine) or GeneTrails Comprehensive Solid Tumor 
and Fusion Gene Panels (Tumors 2–5, Knight Diagnos-
tic Laboratories, OHSU). Overall, 3 out of 5 samples had 
alterations in cancer-related genes and no gene fusion 
products were detected (Table 1).
Index case
Tumor 1 NGS identified a partial PTCH1 deletion of 
exons 15–24 on chromosome 9q (Fig. 1). This mutation 
corresponds to a partial loss of the 4th extracellular loop 
(ECL) and complete loss of the 5th and 6th ECLs, as well 
as loss of transmembrane domains 8 thru 12, the 4th and 
5th intracellular loops (ICLs), and the C-terminus cyto-
plasmic domain. This predicts a loss of tumor suppres-
sor function due to altered inhibition of the SMO proto-
oncoprotein. In addition, the tumor also had genomic 
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alterations in NOTCH1 L2457V (designated as a benign 
genomic alteration in ClinVar) and NOD1 L475fs*35. 
Nucleotide-binding oligomerization domain-containing 
protein 1 (NOD1) involved in the recognition of bacterial 
molecules and stimulation of an immune reaction [22]. 
Thus, we suspect that these are passenger mutations.
Validation cohort
Tumor 2 Tumor 2 had bi-allelic chromosome 9q dele-
tions of PTCH1 and FANCC (Fanconi anemia comple-
mentation group C). FANCC encodes a protein involved 
in homologous recombination repair of damaged DNA 
and delaying apoptosis. Whether loss of FANCC played a 
role in the development of this tumor is unclear. Examina-
tion of the involved chromosomal loci (Chr9: 95,099,054–
95,517,057 from GRCh38/hg38 in UCSC Genome 
Browser [23]) shows that FANCC and PTCH1 are the 
only coding genes located within this position. Loss of 
both FANCC and PTCH1 suggests a long-range deletion 
of chromosome 9 that likely encompassed at least partial 
deletions of both genes. However, it is certainly possible 
Table 1 Demographic and clinical characteristics of the cohort
N/A not applicable, NCI National Cancer Institute, OHSU Oregon Health & Science University, QC quality control, UCSD University of California, San Diego
a Patient 1 represents an index case observation
b No gene deletions detected within the GeneTrails panel of 124 known oncogenes and tumor suppressor genes. Does not rule out the possibility of gene losses in 
those not included in the panel
Patient Age Sex Tumor location Size (cm) Institution Altered chromosome Genes in deletion
1a 65 M Stomach, antrum 5.0 UCSD 9 PTCH1 deletion exons 15–24
2 61 F Duodenum 11.0 NCI 9 PTCH1
FANCC
3 16 M Stomach Unknown NCI 11 and 12 CHEK1 (Chr11)
CDKN1B (Chr12)
DDX11 (Chr12)
ERBB3 (Chr12)
4 43 F Stomach, distal 3.0 NCI N/A None  detectedb
5 48 M Stomach 2.8 OHSU N/A None  detectedb
6 49 F Stomach 3.5 NCI N/A Failed QC
7 15 F Stomach, prepyloric 6.0 NCI N/A Failed QC
8 32 F Stomach, antrum 3.0 NCI N/A Failed QC
b
c
a
Fig. 1 PTCH1 gene schematic. a PTCH1 origin on q arm of chromosome 9, b full length transcript with 24 exons and c mutant PTCH1 with deletion 
of exons 15–24 (Adapted from https ://www.genec ards.org and https ://www.atlas genet icson colog y.org, respectively)
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that the deletion encompassed a larger region that was 
not detected by the GeneTrails panel.
Tumor 3 A third tumor was found to have bi-allelic 
chromosome 12 deletions of CDKN1B, DDX11 and 
ERBB3. CDKN1B encodes  p27Kip1, which regulates cell 
cycle progression by inhibiting cyclin E-CDK2 and cyclin 
D-CDK4. The DDX11 gene encodes a DNA/RNA helicase 
that has myriad functions in maintenance of genomic sta-
bility, chromosomal organization in mitosis and transla-
tion initiation. ERBB3 encodes HER3 (human epidermal 
growth factor receptor 3), which has not been found to 
be independently oncogenic but forms active heterodi-
mers with ErbB2. The loci of genes affected [CDKN1B 
(12p13.1), DDX11 (12p11.21), and ERBB3 (12q13.2)] are 
distributed throughout chromosome 12 suggesting that 
individual alterations, not long-range deletions, occurred. 
Furthermore, proximate and intervening genes such as 
CCND2 (12p13.32), KRAS (12p12.1) and MDM2 (12q15) 
were found to be intact, also suggesting that the chromo-
some 12 deletions were partial (or full) gene deletions of 
individual loci rather than long-range deletions. Tumor 
3 also had bi-allelic loss of CHEK1 on chromosome 11. 
Checkpoint kinase 1 (Chk1), the protein product of 
CHEK1, is involved in surveillance of genomic integrity 
and is necessary for initiation of the DNA damage check-
point. We suspect that CHEK1 (11q24.2) was altered by 
a partial or full-length deletion rather than a long-range 
deletion because an neighboring gene, SDHD (11q23), 
was intact. However, a long-range deletion that encom-
passed other genes than CHEK1, but were not assessed by 
the GeneTrails panel, cannot be excluded.
Tumors 4–5 Two tumors did not have any cancer-asso-
ciated genetic alterations detected on NGS by the Gene-
Trails panel (124 known oncogenes and tumor suppressor 
genes), although this does not rule out that other genes 
may be involved in tumorigenesis.
Tumors 6–8 Three tumors did not meet minimum 
requirements for DNA quality for analysis by NGS.
Hh pathway is expressed in PTCH1‑inactivated PF
Tumors 1 and 2 both had genetic alterations causing 
loss of the PTCH1 gene. To assess whether PTCH1 dele-
tion was associated with activation of Hh signaling, we 
performed quantitative RT-PCR analysis of Hh path-
way components and Hh target genes. Fresh tumor tis-
sue was available from Tumor 1 (index case) and was 
utilized for in  vitro assays. This analysis demonstrated 
mRNA expression of Hh pathway components (PTCH1, 
SMO, GLI1, GLI2 and GLI3) as well as downstream GLI1 
transcriptional targets (CCND1 and HHIP) (Fig. 2). It is 
noteworthy that PTCH1 and GLI1 are both Hh pathway 
components and are also GLI1 transcriptional targets. In 
the tumor, the Hh pathway ligands, SHH and IHH, had 
undetectable expression consistent with ligand-inde-
pendent Hh pathway activation following PTCH1 inacti-
vation (Additional file 1: Figure S1).
PTCH1‑inactivated PF is sensitive to targeted Hh inhibition
We next performed cell killing assays with a SMO proto-
oncoprotein inhibitor to assess the cellular dependency 
on Hh signaling. Viable tissue from Tumor 1 was dissoci-
ated into single cell suspension and plated in cell culture. 
Treatment of the primary tumor cells with the Hh path-
way inhibitor, sonidegib (LDE225, Novartis), resulted in 
dose-dependent cell killing with an  IC50 of 27 μM (Fig. 3 
and Additional file  1: Figure S2). Drug dose range was 
selected for  IC50 finding based on literature cited values 
[19–21]. Thus, targeting PTCH1-mutant PF cells with a 
SMO inhibitor resulted in tumor cell death.
Discussion
In a recent study, GLI1 upregulation through a MALAT1-
GLI1 fusion or copy number amplification was detected 
in a subset of PF [5]. Spans et al. demonstrated the critical 
nature of Hh signaling in this disease. Here, we identified 
two cases of plexiform fibromyxoma (PF) with genomic 
loss of PTCH1, a tumor suppressor gene in the hedgehog 
b
a
Fig. 2 Hedgehog pathway is expressed in PTCH1‑inactivated 
plexiform fibromyxoma. a Validation of transcript PCR products on 
agarose gel electrophoresis (cropped as shown; full length gel is 
presented in Additional file 1: Figure S1) and b relative quantification 
of expressed hedgehog pathway components using the delta‑Ct 
method. Experiments performed in triplicate (N = 3)
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pathway. Quantitative PCR of one of these tumors sup-
ported ligand-independent activation of the Hh path-
way. In addition, targeting smoothened in the context of 
PTCH1 inactivation resulted in cell killing of primary PF 
cells. This approach represents the first in vitro use of a 
targeted therapeutic strategy for this rare tumor.
Our new findings lend further support for a primary 
role of aberrant Hh signaling in PF pathophysiology. In 
contrast to the previously reported GLI1 alteration, we 
observed loss of PTCH1, indicating that events occurring 
upstream in the Hh pathway can also drive PF growth [5]. 
Although it is possible that non-canonical activation of 
the Hh pathway accounts for the expression of Hh path-
way components, we believe this is unlikely since non-
canonical Hh activation usually results in low SMO levels 
whereas Smo mRNA was found to be high in Tumor 1 
[24, 25]. We also show that targeted SMO inhibition 
in vitro, which lies downstream of PTCH1, but upstream 
of GLI1, leads to dose-dependent cell killing of PF cells. 
This supports the role of PTCH1/SMO-axis oncogenesis 
since non-canonical Hh activation is SMO-independent 
and usually resistant to SMO inhibition. In contrast to 
PTCH1-mutated PF, GLI1 upregulated PFs are predicted 
to be resistant to SMO inhibition. Thus, our new find-
ings provide evidence for a possible therapeutic role of 
Hh inhibition in the treatment of PTCH1-inactivated PF. 
Additional testing using in vivo models will be necessary 
to determine whether SMO inhibition is a viable strategy 
for treating patients with PTCH1-inactivated PF.
Hedgehog signaling has been associated with several 
tumor types. In fact, germline PTCH1 mutations under-
lie nevoid basal-cell carcinoma syndrome, also known 
as Gorlin Syndrome. This is an autosomal dominant 
condition associated with distinctive facial abnormali-
ties, as well as, basal cell carcinomas and mesenchymal 
tumors. Interestingly, histopathologic features of tumors 
associated with Gorlin Syndrome bear striking simi-
larities to plexiform fibromyxoma. For example, Gorlin-
associated odontogenic myxofibrous tumors have a bland 
myxoid appearance in a plexiform pattern [26]. Similarly, 
a subset of pediatric gastric pericytomas have been asso-
ciated with an ACTB-GLI1 gene fusion [27]. Additionally, 
six cases of malignant epithelioid neoplasms with fre-
quent S100-positivity were all found to have GLI1 fusions 
involving ACTB, MALAT1 or PTCH1 [28]. These tumors 
may represent a histologically novel class of pericytoma 
or soft tissue sarcoma distinct from plexiform fibromyx-
oma. Collectively, these observations underscore a strong 
genotypic-to-histopathologic/morphologic relationship 
in PTCH1 associated diseases.
In addition to syndromic diseases, PTCH1 mutations 
have been implicated in several cancers including spo-
radic basal cell carcinoma (BCC) [29], squamous cell 
carcinoma [30], medulloblastoma [8], and embryonal 
rhabdomyosarcoma [31]. There are over 500 PTCH1 
mutations described in human disease [14]. The mono-
allelic exon 15–24 deletion of PTCH1 in Tumor 1 would 
be predicted to truncate the C-terminal region. Interest-
ingly, elegant mutagenesis experiments in Drosophila 
have shown that the C-terminus of ptch1 is necessary for 
inhibition of the Hh pathway and that deletion of the last 
156 residues produces a ligand-independent dominant 
negative phenotype [32, 33]. Consistent with these data, 
PTCH1 haploinsufficiency has been reported in variety 
of cancer types, including basal cell carcinoma, medul-
loblastoma, and rhabdomyosarcoma [34]. Furthermore, 
“one-hit” PTCH1 inactivation has been described in up 
to one-third of patients with nevoid basal cell carcinoma 
syndrome (NBCCS) who have mono-allelic PTCH1 
mutations [35]. Taken together, this suggests that single 
allele inactivation of PTCH1 can have a dominant nega-
tive effect and may account for Hh activation, as well as 
tumorigenesis, in a subset of PF.
Based on the prior observation of GLI1 overexpression 
in PF and the present identification of PTCH1 inactiva-
tion, it appears that there are two distinct subsets of PF 
identified to date. It is interesting to note that the previ-
ously reported MALAT1-GLI1 fusion protein implicates 
chromosomal loci 11q13 (MALAT1) and 12q13 (GLI1). 
Tumor 3 from our cohort showed loss of ERBB3 (12q13; 
close to GLI1) and CHEK1 (11q24). Unfortunately, the 
RNA from this case was too degraded to screen for a pos-
sible GLI1 fusion.
There are several limitations to our study. First, primary 
cells were expanded in culture for several days before 
performing cell killing assays. Therefore, it is possible 
Fig. 3 Dose‑dependent cell death in PTCH1‑inactivated PF following 
SMO inhibitor treatment. Four‑point dose titration of sonidegib 
treatment. Absolute experimental and control data shown in 
Additional file 1: Figure S2. Experiments performed in triplicate 
(N = 3). *P < 0.001
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that these cells do not fully recapitulate in  vivo biology. 
Second, the PF cells were not immortalized and we were 
limited in the amount of in  vitro studies that could be 
performed before viable cells were exhausted. Thus, 
additional mechanistic studies including genetic PTCH1 
rescue experiments, SMO knockdown experiments, and 
assessment of Hh target gene expression following SMO 
inhibitor treatment were not feasible. Development of an 
immortalized PF cell line would prove an extremely use-
ful tool in further characterization of PF pathophysiology.
Conclusions
We report a novel association between PTCH1 inacti-
vation and the development of plexiform fibromyxoma. 
Our findings demonstrate that tumor suppressor gene 
alterations (i.e., PTCH1), rather than oncogenic muta-
tions (i.e., GLI1), within the Hh pathway are also associ-
ated with plexiform fibromyxoma. In turn, targeted Hh 
pathway inhibition with SMO antagonists may repre-
sent a target to study for treating a subset of plexiform 
fibromyxomas. Further studies are warranted to investi-
gate the clinical efficacy of these agents in appropriately 
selected patients, as well as to determine the underlying 
biology of tumors lacking PTCH1 and GLI1 alterations.
Additional files
Additional file 1: Figure S1. Validation of transcript PCR products on 
agarose gel electrophoresis (full length gel). 
Additional file 2: Figure S2. Absolute experimental and control data for 
cell viability assay.
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